Bausch + Lomb Vision-Correction Surgery Platform Approved in U.S. by FDA
08 1월 2024 - 9:41PM
Dow Jones News
By Adriano Marchese
Bausch + Lomb said Monday that its laser-assisted vision
correction surgery platform to treat nearsightedness was approved
by the U.S. Food and Drug Administration.
The Canadian eye-health company said the FDA has approved the
Teneo Excimer Laser Platform for laser-assisted in situ
keratomileusis, also known as Lasik, vision correction surgery for
myopia and myopic astigmatism.
Bausch + Lomb said that Teneo has been adopted in more than 50
countries around the world.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 08, 2024 07:26 ET (12:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Bausch and Lomb (TSX:BLCO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Bausch and Lomb (TSX:BLCO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
